AI Article Synopsis
- * Key updates include clearer definitions of red cell transfusion dependency and the use of the Myeloproliferative Neoplasm Symptom Assessment Form for tracking symptom changes.
- * Six response categories are outlined, including complete and partial remission, as well as clinical and symptom improvements, with additional guidelines for assessing disease progression and remission status.
Article Abstract
The current document is a revision of the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for treatment response in myelofibrosis (MF) and represents a collaborative effort by the IWG-MRT and the European LeukemiaNet to objectively assess the value of new drugs in inducing morphologic remission or improvement in MF-associated symptomatic burden (MF-SB). Some of the changes in the current revision include stricter definitions of red cell transfusion dependency and independency and consideration of the Myeloproliferative Neoplasm Symptom Assessment Form as a tool to quantify meaningful changes in disease-related symptoms. Six response categories are listed: complete remission (CR) and partial remission signify treatment effects that are consistent with disease modification, whereas drug-induced improvements in MF-SB were annotated as clinical improvement, anemia response, spleen response, or symptoms response. Additional criteria are provided for progressive disease, stable disease, and relapse. The document also includes recommendations for assessing cytogenetic and molecular remissions, without mandating their inclusion for CR assignment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828070 | PMC |
| http://dx.doi.org/10.1182/blood-2013-03-488098 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Amidine-functionalized aggregation-induced emission luminogen and a 3D-printed digital sensor platform for ultrafast and visual detection of heparin.
Anal Chim Acta
February 2025
College of Chemistry, Henan Joint International Research Laboratory of Green Construction of Functional Molecules and Their Bioanalytical Applications, Food Laboratory of Zhongyuan, Zhengzhou University, Zhengzhou, 450001, China.
Background: Heparin is a widely used anticoagulant in clinic. However, improper dosing can increase the risk of thromboembolic events, potentially leading to life-threatening complications. Clinic monitoring of heparin is very important for its use safety.
View Article and Find Full Text PDFPoint of view: Challenges in implementation of new immunotherapies for Alzheimer's disease.
J Prev Alzheimers Dis
January 2025
Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, BioClinicum, 171 64 Solna, Sweden; Theme Inflammation and Aging, Karolinska University Hospital, 141 86 Stockholm, Sweden.
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. However, significant challenges persist that could impede the successful integration of this class of drugs into clinical practice. These challenges include determining patient eligibility, appropriate use of diagnostic tools and genetic testing in patient care pathways, effective detection and monitoring of side effects, and improving the healthcare system's readiness by engaging both primary care and dementia specialists.
View Article and Find Full Text PDFInformal care for people with dementia in Europe.
J Prev Alzheimers Dis
January 2025
Division of Neurogeriatrics, Department of Neurobiology Care Sciences and Society; Karolinska Institutet; Sweden; BioClinicum J9:20, Akademiska stråket, 171 64 Solna, Sweden.
Introduction: Informal care estimates for use in health-economic models are lacking. We aimed to estimate the association between informal care time and dementia symptoms across Europe.
Methods: A secondary analysis was performed on 13,529 observations in 5,369 persons from 9 European pooled cohort or trial studies in community-dwelling persons with dementia.
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.
J Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
Community health system capacities and capabilities within an evolving community health policy framework: mixed methods study of stakeholders in central Uganda.
BMJ Open
January 2025
Department of Health Policy Planning and Management, Makerere University School of Public Health, Kampala, Uganda
Objectives: Empowering communities through identifying and unlocking community capacities and capabilities is vital for improving community health systems. This study assessed the community health system's status quo and readiness for implementing a government-led, partner-supported community health worker project.
Design: A mixed methods cross-sectional study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!